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INTRODUCTION
Statins for primary prevention of 
cardiovascular disease (CVD) have been 
shown to be effective in reducing all-cause 
mortality, coronary heart disease events, 
and strokes.1 CVD risk (determined from a 
combination of age, sex, and cardiovascular 
risk factors) predicts benefit; therefore, 
estimating CVD risk identifies patients who 
should be offered statins.2
CVD risk assessment has been a 
fundamental part of clinical guidance on 
CVD prevention in the UK and internationally 
for two decades.3–5 In the UK, an absolute 
risk of CVD greater than a threshold was, 
and remains, the main criterion for offering 
statins.6,7 The National Institute for Health 
and Care Excellence (NICE)7 recommends 
that GPs use QRISK2 (introduced in 2012) 
to estimate 10-year CVD risk.2 Other risk 
calculators were used before this and were 
still available after 2012.
Estimated CVD risk is the best predictor 
of the benefits of statin treatment and 
is essential for effective shared decision 
making.8 Evidence suggests that the use 
of risk scoring improves the accuracy of 
perceived CVD risk and medical prescribing 
without causing harms.9,10 The use of CVD 
risk scoring should result in more targeted 
prescribing, but there is evidence both of 
undertreatment of high-risk patients and 
overtreatment of low-risk patients.11–15 
This may be because risk scores are not 
consistently used by clinicians16 or because 
clinical information not incorporated into 
the risk scores is being taken into account. 
In 2014, the NICE guidelines for England 
and Wales on lipid modification reduced 
the CVD risk threshold for offering statins 
from 20% to 10% 10-year risk.6,7 The 
benefit of lowering the threshold has been 
questioned.17 The medical community and 
lay media have raised concerns about 
overprescribing of statins, questioning the 
clinical benefit and potential for harm.18,19 
The aim of this study is to examine how 
trends in initiating statins for the primary 
prevention of CVD relate to QRISK2 scoring 
and how these have changed over recent 
years, with particular focus on the impact 
of the 2014 NICE guidance. This will provide 
new information on the impact of, and 
adherence to, clinical guidelines in the UK.
METHOD
This was a historical cohort study using data 
from anonymised primary care records of 
practices in England and Wales contributing 
to The Health Improvement Network (THIN) 
database. The authors had full access to the 
database. THIN has been used in previous 
studies to validate QRISK2 and it was shown 
that the discrimination statistics in THIN are 
as good as those for the original QRISK2 
cohort.20,21 Practices that contribute to THIN 
use the Vision (In Practice Systems) electronic 
patient records system.22 Clinical data are 
coded using Read Code clinical classification 
version 2,23 and drug codes correspond to 
the British National Formulary.24 Codes used 
are available from the authors on request.
Research
Abstract
Background
Statin prescribing should be based on 
cardiovascular disease (CVD) risk, but evidence 
suggests overtreatment of low-risk groups and 
undertreatment of high-risk groups. 
Aim
To investigate the relationship between CVD risk 
scoring in primary care and initiation of statins 
for the primary prevention of CVD, and the effect 
of changes to the National Institute for Health 
and Care Excellence (NICE) guidance in 2014.
Design and setting
Historical cohort study using UK electronic 
primary care records. 
Method
A cohort was created of statin-naïve patients 
without CVD between 1 January 2000 and 
31 December 2015. CVD risk scores (calculated 
using QRISK2 available from 2012) and statin 
initiations were identified. Rates of CVD 
risk score recording were calculated and 
relationships between CVD risk category (low-, 
intermediate-, and high-risk: <10%, 10–19.9%, 
and ≥20% 10-year CVD risk) and statin initiation 
were analysed.
Results
A total of 1.4 million patients were identified 
from 248 practices. Of these, 151 788 had a 
recorded CVD risk score since 2012 (10.67%) 
and 217 860 were initiated on a statin (15.31%). 
Among patients initiated on a statin after 2012, 
27.1% had a documented QRISK2 score: 2.7% 
of low-risk, 13.8% of intermediate-risk, and 
35.0% of high-risk patients were initiated on 
statins. Statin initiation rates halved from a peak 
in 2006. After the 2014 NICE guidelines, statin 
initiation rates declined in high-risk patients but 
increased in intermediate-risk patients.
Conclusion
Most patients initiated on statins had no 
QRISK2 score recorded. Most patients at high 
risk of CVD were not initiated on statins. One 
in six statin initiations were to low-risk patients 
indicating significant overtreatment. Initiations 
of statins in intermediate-risk patients rose 
after NICE guidelines were updated in 2014.
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To maintain a stable cohort, only practices 
that contributed data for the whole study 
period (from the beginning of 2000 to the 
end of 2015) were included. Patients had 
to be suitable for CVD risk assessment 
according to NICE guidance,6 and should 
not have been prescribed statins (or 
other lipid-lowering therapy) in the past. 
Patients with chronic kidney disease stages 
3–5, type 1 diabetes mellitus, or familial 
hypercholesterolaemia were excluded as 
risk assessment is not required for statin 
initiation. Patients were eligible for inclusion 
from the earliest of the following dates: 
study start date, acceptable mortality 
reporting date (which ensures that patient 
deaths and deregistrations are being 
recorded consistently), Vision installation 
date plus 1 year, registration date plus 
1 year (to ensure time for baseline data to 
be recorded), and age 40 years; until the 
earliest of the following dates: age 85 years, 
study end date, CVD diagnosis, statin 
initiation, recording of a contraindication 
for the prescribing of statins, death, and 
transfer out of the practice. 
All QRISK2 scores recorded during the 
study period were included (individuals 
may have had several scores recorded). 
Practice ID, country, ethnicity, Townsend 
deprivation quintile, sex, and year of birth 
were identified. Patients with missing sex or 
year of birth, or a QRISK score greater than 
99.99%, were excluded. A ‘missing’ category 
was used for other missing data.
Primary analysis
Following a descriptive analysis of the 
cohort, the rates of statin initiations and 
QRISK2 recording per year were calculated. 
Sub-analyses were performed to establish 
these rates by demographic variables (sex, 
age, and Townsend deprivation quintile). 
Rates were not adjusted for these variables.
Secondary analysis
Relationship between QRISK2 scoring 
and statin initiation. QRISK2 scores were 
categorised into low (<10%), intermediate 
(10–19.9%) and high (>20%) 10-year CVD 
risk. In each category, the proportion 
of patients initiated on statins following 
QRISK2 scoring was established based on 
the patient’s latest record. 
Coded CVD prevention encounters 
were categorised into QRISK2 score with 
subsequent statin initiation, QRISK2 score 
without statin initiation, and statin initiation 
without prior QRISK2 score. The proportion 
of initiations with/without a recorded 
QRISK2 score were reported by patient 
demographic characteristics. Statistical 
significance was assessed using Pearson’s 
χ2 tests.
Impact of NICE guidance. The mean 
recorded QRISK2 score for patients initiated 
on statins was calculated before and after 
the updated NICE guideline publication 
(July 2014). The annual proportion of statin 
initiations in each QRISK2 category (risk 
scores within 60 days of prescribing) was 
reported from 2012 to 2015 to reveal any 
change in the pattern of prescribing.
RESULTS 
After excluding three patients who had a 
QRISK2 score greater than 99.99%, the 
cohort consisted of 1 422 664 patients from 
248 practices, with a total of 9 437 754 
patient-years of follow-up between 2000 
and 2015. The median observation period 
was 5.65 years (interquartile range: 
2.50 years–10.50 years). A total of 217 860 
patients were initiated on a statin (15.31%, 
95% confidence intervals (CI) = 15.25% 
to 15.37%) and 151 788 patients had at 
least one QRISK2 score recorded (10.67%, 
95% CI = 10.62% to 10.72%). Of the 
patients with a recorded QRISK2 score, 
80.2% had just one score, 15.1% had two 
scores, and 4.6% had more than two scores 
recorded (range 3–13). The demographic 
characteristics of the cohort are shown in 
Table 1.
Statin initiation trends
From 2000 to 2006 there was an increase 
in the rate of statin initiations from 9.05 
(95% CI = 8.66 to 9.45) initiations/1000 
How this fits in
This study confirms that there is potential 
undertreatment of patients at high risk 
of cardiovascular disease (CVD) and, 
although only a small proportion of 
low-risk patients are initiated on statins, 
low-risk patients represent a significant 
proportion of all statin initiations. The 
study has also demonstrated that the 
reduction in risk threshold for offering 
statins recommended in the 2014 National 
Institute for Health and Care Excellence 
guidelines has not resulted in the massive 
increase in statin initiations that was 
anticipated. This study indicates that only 
one-quarter of patients have evidence 
of formal CVD risk assessment with 
QRISK2 before statin initiation despite the 
fact that this is essential information for 
shared decision making and to determine 
treatment eligibility. 
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patient-years to 34.41 (95% CI = 33.95 to 
34.87) initiations/1000 patient-years. The 
rate then declined to 17.26 (95% CI = 16.95 
to 17.57) initiations/1000 patient-years in 
2015 (Figure 1). Males had a higher overall 
annual initiation rate than females (25.5 
versus 20.9, P<0.001) (not adjusted for 
other characteristics).
Trends in the recording of QRISK scores
From the introduction of the QRISK2 
code (2012) until 2015, there was a steady 
increase in the recording of QRISK2 scores 
from 31.6 (95% CI = 30.2 to 33.1) to 99.1 
(95% CI = 96.6 to 101.7) per 1000 patient-
years. Females had an overall unadjusted 
rate of QRISK2 recording of 61.4 (95% 
CI = 61.0 to 61.8) scores/1000 patient-years 
compared with 51.7 (95% CI = 51.3 to 52.1) 
QRISK2 scores/1000 patient-years for 
males. 
Association between QRISK2 scores and 
statin initiation
Most patients who had a QRISK2 score 
documented did not subsequently have a 
statin prescribed (90.2%, 95% CI = 90.0% 
to 90.3%). Table 2 shows the number of 
patients in each QRISK2 category and 
the proportion initiated on a statin. Low-, 
intermediate-, and high-risk patients 
accounted for 16.6%, 37.1%, and 46.3% of 
all patients prescribed a statin following 
recorded QRISK2 assessment.
Since 2012, 72.9% (95% CI = 72.5% to 
73.3%) of patients initiated on a statin did 
not have a QRISK score recorded at any 
time. The outcomes of clinical encounters 
involving the initiation of statins or recording 
of QRISK2 score are illustrated in Figure 2. 
Table 3 demonstrates the variations in 
these outcomes for different demographic 
groups. The proportion of statin initiations 
that occur without a recorded QRISK2 score 
was relatively consistent, with the notable 
Table 1. Demographic characteristics of cohort (n = 1 422 664)
   Statin initiation  QRISK recording 
   rate, (95% CI)  rate, (95% CI) 
Variable  n (%) (initiations/1000 patient-years)a (scores/1000 patient-years)a
Sex Male 693 403 (48.7) 25.5 (25.4 to 25.7) 51.7 (51.3 to 52.1) 
 Female 729 261 (51.3) 20.9 (20.8 to 21.0) 61.4 (61.0 to 61.8)
Age group (on entering cohort), years 40–59 779 566 (54.8) 8.3 (8.2 to 8.4) 43.3 (42.9 to 43.7) 
 50–59 304 440 (21.4) 21.7 (21.5 to 21.8) 61.8 (61.3 to 62.4) 
 60–69 186 641 (13.1) 42.1 (41.8 to 42.4) 81.2 (80.4 to 82.0) 
 ≥70 152 017 (10.7) 41.7 (41.4 to 42.1) 51.8 (51.0 to 62.6)
Townsend deprivation quintile 1st (least) 397 251 (27.9) 20.6 (20.5 to 20.8) 56.4 (55.9 to 57.0) 
 2nd 321 663 (22.6) 22.5 (22.3 to 23.2) 59.3 (58.7 to 59.9) 
 3rd 299 183 (21.0) 23.4 (23.2 to 23.7) 57.7 (57.0 to 58.3) 
 4th 239 649 (16.8) 25.6 (25.4 to 25.9) 53.8 (53.1 to 54.5) 
 5th (most) 143 353 (10.1) 27.8 (27.4 to 28.1) 55.2 (54.2 to 56.2) 
 Missing 21 565 (1.5) 22.8 (21.8 to 23.8) 58.1 (55.7 to 60.6)
Ethnicity Asian 21 993 (1.5) 33.8 (32.7 to 34.9) 87.0 (84.2 to 89.9) 
 Black 18 361 (1.3) 20.7 (19.7 to 21.6) 64.4 (61.9 to 67.0) 
 Chinese 2668 (0.2) 18.7 (16.6 to 21.2) 64.2 (57.8 to 71.3) 
 Mixed 3929 (0.3) 19.0 (17.1 to 21.1) 77.6 (71.7 to 84.0) 
 Other 6389 (0.4) 22.3 (20.6 to 24.1) 73.5 (68.9 to 78.4) 
 White 516 436 (36.3) 25.6 (25.4 to 25.8) 72.0 (71.5 to 72.5) 
 Missing 852 888 (60.0) 21.4 (21.3 to 21.5) 43.8 (43.4 to 44.1)
aFrom 2012 to 2015 inclusive. CI = confidence interval.
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Figure 1. Rate of statin initiation by age group 
2000–2015.
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exception that younger patients seemed 
to have a higher proportion of initiations 
without a recorded risk assessment.
Impact of NICE guidance on QRISK2 
scoring and statin prescribing
When examining risk scores that were 
calculated within 60 days of statin initiation, 
the mean QRISK2 score before the 2014 
guidance was 23.06, dropping to 19.28 after 
July 2014 (P≤0.001). Figure 3 shows that an 
increasing proportion of statin initiations 
occur in the 10–19.9% QRISK2 category in 
2014/2015 while initiations in the high-risk 
category (>20%) continue on a declining 
trajectory.
For patients with a recorded QRISK2 
score (at any time), the proportion of 
statin initiations that were consistent with 
prevailing NICE guidelines increased from 
51.9% (2008 guideline) to 85.3% (2014 
guideline) (Table 2). This change is mostly 
accounted for by the patients with a QRISK2 
score of 10–19.9%.
DISCUSSION
Summary
The rate of statin initiations has halved since 
2006. The initial peak in statin initiations 
may have been influenced by a dramatic 
reduction in the cost of prescribing when 
simvastatin came off patent in 2003. In 
addition, there were major publications on 
CVD prevention around this time including 
the Joint British Societies’ guidelines 
and a NICE technological appraisal 
recommending the use of statins.25,26 This 
may have resulted in saturation of the 
population of patients who were eligible 
and willing to take statins over the next 
few years. This could explain the decline 
in initiations from 2006 to 2015, as patients 
who could potentially be prescribed statins 
would be the newly eligible (lower risk) 
or those less active in seeking treatment. 
Additionally, over this period there was 
increased focus on the adverse effects of 
statins because data from observational 
studies differed from trial findings,27 which 
may have influenced both the clinicians’ 
decision to prescribe, and the patients’ 
decision to accept, treatment.
The rate of QRISK2 coding has shown a 
steady increase since it became available 
in 2012. Most patients who had a QRISK2 
score calculated were not prescribed a 
statin in the following 60 days, even those 
found to be in the high-risk category. It is 
not possible to establish whether those 
patients who were above the threshold 
to be prescribed a statin did not receive 
treatment because they were not offered 
it or because they declined an offer. Older 
patients (aged >70 years) were less likely to 
have a QRISK2 score recorded than patients 
aged 50–69 years. Younger patients were 
more likely to be initiated on statins without 
recorded QRISK2 assessment than older 
patients.
Most patients initiated on statins since 
2012 did not have a prior QRISK2 score 
recorded. Of those that did, one in six patients 
were in the low-risk category and should 
not have been offered a statin according 
to NICE guidance. These findings indicate 
that factors other than risk score were 
Table 2. Proportion of patients with previous CVD risk assessment 
initiated on statins by QRISK2 category and time period
 QRISK2 Patients initiated  Total patients Guideline-congruent 
Period category on statin, n (%) in category, n initiations, n (%)
2012 to 2015 ≥20% 6923 (35.0) 19 781  
 10–19.9% 5545 (13.8) 40 272  
 0–9.9% 2481 (2.7) 91 735  
 Total 14 949 (9.8) 151 788 N/A
Pre-guideline change ≥20% 3862 (36.7) 10 531  
(January 2012 to June 2014)  10–19.9% 2198 (12.8) 17 117  
 0–9.9% 1381 (3.6) 38 258  
 Total 7441 (11.3) 65 906 3862 (51.9)
Post-guideline change ≥20% 3061 (33.1) 9250  
(July 2014 to December 2015)  10–19.9% 3347 (14.4) 23 155  
 0–9.9% 1100 (2.1) 53 477  
 Total 7508 (8.7) 85 882 6408 (85.3)
A QRISK2 score was
recorded in 80% of
all encounters
Statins were
initiated in
27.5% of all
encounters
7.5% of encounters had
both a QRISK2 score and
subsequent statin
initiation
Figure 2. Coded outcomes of CVD prevention clinical 
encounters (an encounter may include more than 
one consultation).
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being considered when initiating statins. It 
is possible that clinicians were responding 
to individual patient preference when 
prescribing to low-risk patients, but without 
a discussion about risk (informed by a risk 
estimate) these preferences cannot be fully 
informed. It appears that the 2014 NICE 
guidance changed clinicians’ behaviour as 
the rate of statin initiation among patients 
in the intermediate-risk category (10–19%) 
increased while the high-risk initiation rate 
continued to decrease. 
Strengths and limitations
THIN includes a large number of practices 
that are generalisable to the UK population.28 
This permits identification of prescribing 
trends across large numbers of patients 
over a 16-year period. This period included 
18 months of data after the publication of 
the 2014 NICE guidance, which is sufficient 
time to identify changes in prescribing 
and coding behaviour. Prescribing data is 
well recorded because prescriptions are 
generated and recorded by the clinical 
system. 
Only QRISK2 scores that were entered 
automatically or manually as coded data 
in the electronic patient record could be 
identified. It is possible that clinicians 
calculated a QRISK2 score but did not 
enter it as coded data. This would result 
in an underestimate of the rate of QRISK2 
scoring and the proportion of patients being 
prescribed a statin after QRISK2 score. 
Additionally, some clinicians may have used 
alternative risk calculators in their decision 
making. Risk scores calculated using an 
alternative calculator were not identified 
and this may lead to an underestimate 
of the use of risk estimation in decision 
making.
The study assumed that a QRISK2 score 
within 60 days of statin initiation was likely to 
be taken into consideration when deciding if 
a statin should be initiated. It is possible 
the QRISK2 score was not considered, or 
that scores older than 60 days featured in 
the decision. The latter would lead to an 
underestimate of the proportion of patients 
initiating statins on the basis of QRISK2 
score.
Importantly, the decision to prescribe 
statins is a clinical decision and should not 
Table 3. Variation in QRISK2 score recording and statin prescribing according to demographic group from 
clinical encounters relating to CVD in 2012–2015
   QRISK2 score, Statin initiated Proportion of 
  QRISK2 score,  subsequent  without  initiations without 
Characteristic  no statin, n (%) statin, n (%) QRISK2, n (%) QRISKa
Sex Male 54 874 (67.5) 7134 (8.8) 19 281 (23.7) 0.73 
 Female 79 438 (76.3) 6691 (6.4) 17 934 (17.2) 0.73
Age group, years 40–49 42 913 (84.7) 1347 (2.7) 6396 (12.6) 0.83 
 50–59 43 924 (75.6) 3255 (5.6) 10 943 (18.8) 0.77 
 60–69 33 007 (65.0) 5542 (10.9) 12 201 (24.0) 0.69 
 ≥70 11 468 (50.2) 3681 (16.1) 7675 (33.6) 0.68
Townsend deprivation quintile 1st 40 004 (74.4) 3669 (6.8) 10 080 (18.8) 0.73 
 2nd  31 760 (73.4) 3425 (7.9) 8087 (18.7) 0.70 
 3rd  27 546 (72.0) 2896 (7.6) 7804 (20.4) 0.73 
 4th  19 185 (68.2) 2272 (8.1) 6654 (23.7) 0.75 
 5th 10 829 (66.5) 1380 (8.5) 4072 (25.0) 0.75 
 Missing 4988 (87.7) 183 (3.2) 518 (9.1) 0.74
Total  134 312 (72.5) 13 825 (7.5) 37 215 (20.1) 0.73
aProportions in bold show significant trend (P<0.001) by Pearson’s χ2 test.
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prior to statin initiation.
5  British Journal of General Practice, Online First 2017
be based on QRISK2 score alone. Patient 
preferences, comorbidities, and individual 
patient circumstances will all inform 
the shared decision to prescribe statins. 
Some guideline-incongruent decisions will 
have been clinically justifiable but it is not 
possible to identify this from the data. 
Comparisons with existing literature
The peak in statin initiation in 2006 has 
previously been reported by O’Keeffe et 
al29 who used the same database so the 
initiation patterns are identical. However, 
their study ended in 2013 so they would not 
have observed any effects of the 2014 NICE 
guidance. 
Matthews et al30 observed a steady 
increase in statin initiations for primary 
prevention between January 2011 and 
October 2013 rather than the decline in 
initiations observed in the current study. 
This may be explained by the fact that 
Matthews et al only identified statin 
initiations for primary prevention in patients 
with a preceding CVD risk score. The results 
of the current study would suggest that 
this definition would exclude up to 75% of 
initiations. 
Other studies considering the relationship 
between risk score and statin prescribing 
have used post hoc risk calculations12,14 
or risk scores that were collected for the 
purpose of research,15 so it is difficult to 
imply that prescribing decisions were 
based on risk scores. Homer et al13 did use 
routinely collected risk scores, but their data 
were limited to a specific geographical area 
and they found that nearly 60% of patients 
suitable for risk assessment had a risk 
score documented. The current study found 
that only 11% of the population had a coded 
risk score, suggesting that Homer et al’s 
results may not be generalisable to the rest 
of England and Wales. 
Balder et al 15 considered whether 
statin prescriptions were consistent 
with guidelines in the Netherlands. They 
classified 66% of prescriptions as guideline-
inconsistent. In the UK, previous studies 
have found that 58.3%12 and 58.1%13 of 
prescriptions were guideline-inconsistent. 
This study found lower rates of guideline-
inconsistent prescribing (48.1%) under 
the 2008 guidance. Guideline-inconsistent 
prescribing decreased to 14.7% from July 
2014, but this is as a result of the guidelines 
changing to be more in keeping with 
practice rather than the other way around. 
Guidelines consistently recommend that 
patients with a CVD risk below 10% should 
not be prescribed statins. However, the 
current study found that 2.7% of patients in 
this category were prescribed a statin (Table 
2), which is lower than other studies (2.9%,15 
3.7%,13 and 5.0%14), suggesting improved 
concordance with guidelines.
Implications for research and practice
As CVD risk estimation is instrumental in 
the decision to initiate statins, all patients 
should have a documented CVD risk score 
before statin initiation. It is possible that 
a higher proportion of statin initiations 
are based on patients’ individual risk than 
the data in this study indicate, but the 
medical record should routinely reflect the 
incorporation of risk score in this decision. 
Further research needs to be carried 
out to understand why some patients do 
not undergo risk assessment before statin 
initiation and on what basis the decision 
to prescribe is founded if risk assessment 
is not used. It is also important to identify 
why low-risk patients are initiated on statins 
and whether high-risk patients who are 
not initiated on statins represent missed 
opportunities to lower CVD risk or an 
appropriate, informed and shared decision.
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